Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 11/20 | 0.47 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.43 |
| ▸ | OTC | P00480 | 1/20 | 0.41 |
| ▸ | FNTA | P49354 | 2/20 | 0.39 |
| ▸ | FNTB | P49356 | 2/20 | 0.39 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.39 |
| ▸ | GNPAT | O15228 | 1/20 | 0.39 |
| ▸ | NPY4R | P50391 | 3/20 | 0.37 |
| ▸ | NPY1R | P25929 | 2/20 | 0.37 |
| ▸ | NPY2R | P49146 | 2/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.37 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18765407 | 1.00 | NOD1 (0.47) | NOD1C3AR1OTCFNTAFNTB | |
| Phosphoric Acid SCHEMBL28622620 | 0.95 | OTC (0.47) | NOD1C3AR1OTCFNTAFNTB | |
| SCHEMBL13585207 | 0.87 | NOD1 (0.59) | NOD1OTCFNTAFNTBPGGT1B | |
| SCHEMBL28050255 | 0.87 | NOD1 (0.59) | NOD1OTCFNTAFNTBPGGT1B | |
| SCHEMBL13585280 | 0.87 | NOD1 (0.59) | NOD1OTCFNTAFNTBPGGT1B | |
| SCHEMBL23408816 | 0.86 | ITGB3 (0.46) | NOD1C3AR1GNPATNPY4RNPY1R | |
| SCHEMBL28531459 | 0.84 | C3AR1 (0.42) | NOD1C3AR1GNPATNPY4RNPY1R | |
| SCHEMBL28531452 | 0.84 | C3AR1 (0.42) | NOD1C3AR1GNPATNPY4RNPY1R | |
| SCHEMBL28622617 | 0.84 | OTC (0.42) | NOD1C3AR1OTCNPY4RNPY1R | |
| SCHEMBL187696 | 0.84 | C3AR1 (0.45) | NOD1C3AR1FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114340590-A | Use of beta-L-aspartyl-L-arginine | 西姆莱斯有限公司 | 2022-04-12 | — | — | CN | claimed |
| US-20250255833-A1 | Compositions Comprising One or More (Bio)-Alkanediols with Antioxidants | SYMRISE AG (DE) | 2025-08-14 | — | — | US | disclosed |
| US-12303468-B2 | Compositions comprising one or more (bio)-alkanediols with antioxidants | SYMRISE AG (DE) | 2025-05-20 | — | — | US | disclosed |
| US-11911347-B2 | Compositions comprising one or more (bio)-alkanediols with antioxidants | SYMRISE AG (DE) | 2024-02-27 | — | — | US | disclosed |
| US-20230293408-A1 | Compositions Comprising One or More (Bio)-Alkanediols with Antioxidants | SYMRISE AG (DE) | 2023-09-21 | — | — | US | disclosed |
| US-20230248663-A1 | Compositions Comprising One or More (Bio)-Alkanediols with Antioxidants | SYMRISE AG (US) | 2023-08-10 | — | — | US | disclosed |
| CN-109475483-B | Aspartyl dipeptides for skin care and cosmetic use | 凯塞尔德国有限公司 | 2022-06-14 | — | — | CN | disclosed |
| CN-114340590-A | Use of beta-L-aspartyl-L-arginine | 西姆莱斯有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-114340590-A | Use of beta-L-aspartyl-L-arginine | 西姆莱斯有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-114340590-A | Use of beta-L-aspartyl-L-arginine | 西姆莱斯有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-20210188905-A1 | COMBINING BETA-DIPEPTIDES AND AMINO ACIDS FOR OPTIMAL NUTRITIONAL SUPPLEMENTATION | CYSAL GMBH (DE) | 2021-06-24 | — | — | US | disclosed |
| EP-3829617-A1 | COMBINING BETA-DIPEPTIDES AND AMINO ACIDS FOR OPTIMAL NUTRITIONAL SUPPLEMENTATION | Cysal GmbH (DE) | 2021-06-09 | — | — | EP | disclosed |
| CN-112654362-A | Combination of beta-dipeptides and amino acids for optimizing nutritional supplementation | 凯塞尔德国有限公司 | 2021-04-13 | — | — | CN | disclosed |
| US-10939692-B2 | Method for culturing aquatic animals with aspartyl-dipeptides | CYSAL GMBH (DE) | 2021-03-09 | — | — | US | disclosed |
| WO-2020025656-A1 | COMBINING BETA-DIPEPTIDES AND AMINO ACIDS FOR OPTIMAL NUTRITIONAL SUPPLEMENTATION | CYSAL GMBH (DE) | 2020-02-06 | — | — | WO | disclosed |
| EP-3364774-B1 | ASPARTYL-DIPEPTIDES FOR AQUACULTURE | CYSAL GMBH (DE) | 2019-09-18 | — | — | EP | disclosed |
| US-20180303128-A1 | Aspartyl-Dipeptides for Aquaculture | CYSAL GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| CN-108347970-A | ASPARTYL-DIPEPTIDES FOR AQUACULTURE | 凯塞尔股份有限公司 | 2018-07-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293408-A1 | Compositions Comprising One or More (Bio)-Alkanediols with Antioxidants | MMP8, CXCL8, IL18 | NOD1 3179/4885C3AR1 553/4885OTC 506/4885 |
| US-20250255833-A1 | Compositions Comprising One or More (Bio)-Alkanediols with Antioxidants | MMP8, CXCL8, IL18 | NOD1 3179/4885C3AR1 553/4885OTC 506/4885 |
| US-12303468-B2 | Compositions comprising one or more (bio)-alkanediols with antioxidants | MMP8, CXCL8, IL18 | NOD1 3179/4885C3AR1 553/4885OTC 506/4885 |
| US-20230248663-A1 | Compositions Comprising One or More (Bio)-Alkanediols with Antioxidants | MMP8, CXCL8, IL18 | NOD1 3179/4885C3AR1 553/4885OTC 506/4885 |
| US-11911347-B2 | Compositions comprising one or more (bio)-alkanediols with antioxidants | MMP8, CXCL8, IL18 | NOD1 3179/4885C3AR1 553/4885OTC 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.